Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales decreased due to the suspension of the condom manufacturing business, delays in launching new product lines, the restructuring of the SP Business, and sluggish sales to major customers. Operating income increased due to higher sales in the Precision Equipment Business, improvements in the cost structure of the Healthcare Division, production rationalization, and the optimization of selling prices. One-time expenses associated with the relocation and consolidation of factories reduced net income.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥6,798,180 thousand (YoY -5.6%) |
| Operating profit | ¥415,771 thousand (YoY +99.4%) |
| Ordinary income | ¥337,771 thousand (YoY +97.6%) |
| Profit attributable to owners of the parent | ¥63,636 thousand (YoY -78.7%) |
| Net income per share | ¥50.20 |
| Total assets | ¥10,270,063 thousand |
| Net assets | ¥4,046,888 thousand |
| Cash flows from operating activities | ¥622,755 thousand |
| Cash flows from investing activities | ¥-57,107 thousand |
| Cash flows from financing activities | ¥-333,415 thousand |
| Cash and cash equivalents at end of period | ¥2,239,705 thousand |
| Full-year earnings forecast | Net Sales ¥7,500 million (YoY +10.3%) / Operating profit ¥480 million (YoY +15.5%) / Ordinary income ¥383 million (YoY +13.4%) / Net income ¥287 million (YoY +351.0%) |
| Segment revenue | Medical Equipment Business ¥2,127,861 thousand (YoY -15.8%) / Precision Equipment Business ¥4,401,135 thousand (YoY +8.1%) / SP ¥86,925 thousand (YoY -77.7%) / Food Containers ¥182,256 thousand (YoY -14.0%) |
| Segment profit | Medical Equipment Business ¥59,081 thousand (YoY +682.6%) / Precision Equipment Business ¥1,021,924 thousand (YoY +43.9%) / SP ¥-51,542 thousand / Food Containers ¥-118,268 thousand |
| Depreciation and amortization | ¥289,657 thousand |
| Impairment loss | ¥172,519 thousand (Medical Equipment Business: ¥145,623 thousand; Precision Equipment Business: ¥6,696 thousand; Food Container Business: ¥20,199 thousand) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥2,845 thousand, Gain on sale of non-current assets ¥9,663 thousand / Extraordinary loss Loss on sale of fixed assets ¥8 thousand, Impairment Losses ¥172,519 thousand, Loss on Disposal of Fixed Assets ¥54,458 thousand, Other ¥16,408 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Material subsequent events | Not applicable. |
| Factors Behind Changes in Business Performance | Net sales decreased due to the suspension of the condom manufacturing business, delays in launching new product lines, the restructuring of the SP Business, and sluggish sales to major customers. Operating income increased due to higher sales in the Precision Equipment Business, improvements in the cost structure of the Healthcare Division, production rationalization, and the optimization of selling prices. One-time expenses associated with the relocation and consolidation of factories reduced net income. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales decreased due to the suspension of the condom manufacturing business, delays in launching new product lines, and the restructuring of the SP Business. Operating income increased due to higher sales in the Precision Equipment Business, improvements in the cost structure of the Healthcare Division, production rationalization, and the optimization of selling prices. Net income decreased because one-time expenses associated with the relocation and consolidation of factories were recorded as an extraordinary loss.